Cargando…

Drug treatment of cystic fibrosis

Cystic fibrosis is the most common life-limiting autosomal recessive condition in Australia. A defect in the cystic fibrosis transmembrane conductance regulator protein affects chloride transport across epithelial cells. Patients with cystic fibrosis produce thick sticky mucus. This causes problems...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruorton, Matthew, Goddard, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584790/ https://www.ncbi.nlm.nih.gov/pubmed/36382177 http://dx.doi.org/10.18773/austprescr.2022.063

Ejemplares similares

Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs
por: Li, Hongyu, et al.
Publicado: (2019)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

Editorial: Mechanisms of Novel Drugs and Gene Modifiers in the Treatment of Cystic Fibrosis
por: Veit, Guido, et al.
Publicado: (2022)

Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
por: Harwood, Kiera H., et al.
Publicado: (2021)

Advances in the Cystic Fibrosis Drug Development Pipeline
por: Esposito, Christine, et al.
Publicado: (2023)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Epidemiology of Nontuberculous Mycobacteria Infection in Children and Young People With Cystic Fibrosis: Analysis of UK Cystic Fibrosis Registry
por: Gardner, Aaron I, et al.
Publicado: (2019)

Gene therapy for the treatment of cystic fibrosis
por: Burney, Tabinda J, et al.
Publicado: (2012)

Cystic Fibrosis
por: Gibson, Lewis E.
Publicado: (1969)

Cystic Fibrosis
por: Dodge, J A
Publicado: (1997)

Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices
por: Orenstein, David M., et al.
Publicado: (2015)

The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Cuthbertson, Leah, et al.
Publicado: (2021)

Brazilian guidelines for the diagnosis and treatment of cystic fibrosis
por: Athanazio, Rodrigo Abensur, et al.
Publicado: (2017)

Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
por: Hurley, Matthew N., et al.
Publicado: (2012)

A multimodal iPSC platform for cystic fibrosis drug testing
por: Berical, Andrew, et al.
Publicado: (2022)

The Microbiome in Cystic Fibrosis
por: Huang, Yvonne J., et al.
Publicado: (2016)

Infections in cystic fibrosis
por: Marks-Austin, Kathy A., et al.
Publicado: (1995)

Inflammation in Cystic Fibrosis
Publicado: (1996)

Porosome in Cystic Fibrosis
por: Jena, Bhanu P.
Publicado: (2014)

Calprotectin in Cystic Fibrosis
por: Rumman, Nisreen, et al.
Publicado: (2014)

When is cystic fibrosis not cystic fibrosis? The importance of appropriately classifying patients
por: Faro, Albert, et al.
Publicado: (2022)

European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre
por: Conway, Steven, et al.
Publicado: (2014)

Assessing Psychosocial Distress in Cystic Fibrosis: Validation of the ‘Distress in Cystic Fibrosis Scale’
por: Finlay, Caroline, et al.
Publicado: (2021)

Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Moustaki, Maria, et al.
Publicado: (2017)

Metagenomic Analysis of Respiratory Tract DNA Viral Communities in Cystic Fibrosis and Non-Cystic Fibrosis Individuals
por: Willner, Dana, et al.
Publicado: (2009)

Burkholderia pseudomallei in cystic fibrosis and treatment complications
por: Radhakrishna, Naghmeh, et al.
Publicado: (2015)

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis
por: Velino, Cecilia, et al.
Publicado: (2019)

Treatment of cystic fibrosis related bone disease
por: Ullal, Jagdeesh, et al.
Publicado: (2021)

Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Alyasin, Soheila, et al.
Publicado: (2018)

Exercise capacity in patients with cystic fibrosis vs. non-cystic fibrosis bronchiectasis
por: Bar-Yoseph, Ronen, et al.
Publicado: (2019)

Microalbuminuria in Patients With Cystic Fibrosis
por: Lind-Ayres, Melanie, et al.
Publicado: (2011)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019)

Predicting CFTR activity with front-runner cystic fibrosis drugs
por: Becq, Frédéric
Publicado: (2015)

Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients
por: Satana, Dilek, et al.
Publicado: (2014)

Export in cystic fibrosis
por: LeBrasseur, Nicole
Publicado: (2004)

Cystic fibrosis revisited
por: Kulkarni, H, et al.
Publicado: (2019)

Vasculitis in Cystic Fibrosis
por: Sposito, Francesca, et al.
Publicado: (2020)

Telemedicine in cystic fibrosis
por: Desimone, Marisa E., et al.
Publicado: (2021)

Obesity in cystic fibrosis
por: Kutney, Katherine A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i6coqpdn37p994m980dshprdde